Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis

• Results Overview

  Upadacitinib (oral medication) worked better and faster than dupilumab (injection) in treating moderate-to-severe eczema, with 72.4% vs 62.6% of patients achieving significant skin improvement at 16 weeks.

• Study Summary

  Num Participants:

  673

  Study Type:

  Rct

  Control Group:

  Subcutaneous Dupilumab 300mg Every Other Week

  Efficacy End Points Treatment:

  {'EASI-75': 72.4, 'EASI-90': 61.6, 'EASI-100': 28.4, 'Worst Pruritus NRS': 67.8}

  Efficacy End Points Control:

  {'EASI-75': 62.6, 'EASI-90': 40.3, 'EASI-100': 7.9, 'Worst Pruritus NRS': 49.6}

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected
  Acne	Low	16.1
  Herpes Zoster	Low	2.0
  Hepatic Disorders	Medium	2.9

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected
  Conjunctivitis	Low	8.8
  Acne	Low	2.7